Adma Biologics (ADMA) Free Cash Flow (2011 - 2025)

Adma Biologics has reported Free Cash Flow for 13 years, with the latest figure at $34.6 million in Q4 2025.

• For the quarter ending Q4 2025, Free Cash Flow fell 27.19% year-over-year to $34.6 million; the trailing twelve-month figure through Dec 2025 stood at $27.8 million (down 74.81% YoY), and the FY2025 full-year result was $27.8 million, down 74.81% from the prior year.
• Free Cash Flow for Q4 2025 stood at $34.6 million, up from -$1.1 million in the prior quarter.
• The five-year high for Free Cash Flow was $47.5 million in Q4 2024, with the low at -$37.1 million in Q4 2021.
• Historically, Free Cash Flow has averaged -$2.9 million across 5 years, with a median of -$9.0 million in 2022.
• Annual changes were most pronounced in 2024 — Free Cash Flow soared 728.77% — and 2025, when it plunged 433.98%.
• Adma Biologics' Free Cash Flow stood at -$37.1 million in 2021, then jumped by 70.04% to -$11.1 million in 2022, then soared by 247.38% to $16.4 million in 2023, then jumped by 189.38% to $47.5 million in 2024, then retreated by 27.19% to $34.6 million in 2025.
• The last three Free Cash Flow figures came in at $34.6 million (Q4 2025), -$1.1 million (Q3 2025), and $18.7 million (Q2 2025), per Business Quant data.